This article is more than 5 years old. Information may no longer be current.
VIDEO: Insights on optimal antithrombotic strategy in patients with diabetes, stable CAD
Click Here to Manage Email Alerts
PARIS — In this video exclusive, Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital, professor of medicine at Harvard Medical School and Cardiology Today Editorial Board Member, provides a deep dive on the THEMIS and THEMIS-PCI trials presented at the European Society of Cardiology Congress.
“THEMIS is the largest trial of diabetes performed to date and THEMIS-PCI is the largest group of patients with diabetes and stents to date,” Bhatt told Healio.
THEMIS evaluated ticagrelor (Brilinta, AstraZeneca) added to low-dose aspirin, compared with aspirin alone, in patients with diabetes and stable CAD, but no history of MI or stroke. THEMIS-PCI, the prespecified subgroup analysis, looked at dual antiplatelet therapy vs. aspirin alone in patients with a history of PCI.
Bhatt provides an overview and interpretation of the findings.
Watch the video for more.